These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33970086)

  • 1. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
    Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
    Perm J; 2021 May; 25():. PubMed ID: 33970086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
    Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
    Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.
    Lin Y; Mok M; Harrison J; Battistella M; Farrell A; Leung M; Cheung C
    Transplant Rev (Orlando); 2023 Jan; 37(1):100729. PubMed ID: 36427372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.
    Singh M; Sharma R; Kumar A
    Curr Drug Saf; 2019; 14(2):87-93. PubMed ID: 30727912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
    Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of SGLT2 Inhibitors in Three Chronic Diseases.
    Ge S; Liu R; Mao Y; Geng C; Wang H; Song K; Tian QB
    Int Heart J; 2023; 64(2):246-251. PubMed ID: 37005318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
    Liu Y; An C; Liu P; Yang F; Zhao Q
    Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Trujillo JM; Nuffer WA
    Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.